A recent clinical trial found that fremanezumab, a migraine prevention drug, successfully reduced both migraine frequency and depressive symptoms in adult patients with comorbid migraine and major depressive disorder. The study involved 353 adult patients from 12 countries, and the results indicated significant improvements in migraine days, depressive symptoms, and quality of life, thus suggesting that fremanezumab may effectively address both migraine and major depressive disorder with a single pharmacologic intervention. Additional research is required to fully comprehend the relationship between migraine control and mood outcomes.

Source: JAMA Neurology